NFE2L2 and hepatocellular carcinoma: Studies have shown that APG as a potent Nrf2 inhibitor significantly sensitizes doxorubicin-resistant hepatocellular carcinoma (HCC) BEL-7402 (BEL-7402/ADM) cells to doxorubicin, increases intracellular concentration of ADM and suppresses tumor growth in a mouse xenograft model.